PIK3CA and cancer: Inavolisib is a recently developed, orally administered, strong p110α inhibitor, which induces a specific degradation of the mutated form of PIK3CA, as already described with taselisib, associated with an exquisite activity in PIK3CA-mutated cancer preclinical models [114,115].